分類: JCN Newswire

TOKYO, Aug 22, 2024 - (JCN Newswire via SeaPRwire.com) - Hitachi High-Tech Corporation announced today the global launch of TM4000PlusIII and TM4000III Tabletop Microscopes equipped with support features for automation and stable operation.The TM Series shrinks the electron microscope to a size capable of being mounted on a tabletop. Thanks to theircompact size and ease of installation, desktop microscopes are widely used not only for R&D, but also in quality controlat manufacturing sites, science education at schools, and other purposes. In manufacturing environments in particular, there is a need to increase the efficiency of observation tasks and streamline operations so that even users with limited expertise can easily observe a large number of samples.The TM4000PlusIII is equipped with automation support features that enable users to create recipes for numerous conditions. Recipes can control functions such as stage position adjustment and magnification, which previouslyneeded to be manually configured every time for each sample. In addition, they come equipped with maintenance features designed to facilitate consistent observation. One such function is a monitoring system that checks the condition of the tungsten filament* and graphically reports its condition. Since tungsten filaments require regular replacement, this function allows users to track the filament lifetime and plan ahead with maintenance tasks to allow for smooth and consistent operation of the tool.*Tungsten filaments: A single part used in the electron gun of an electron microscope. They are typically made by bending a thin wire made of tungsten (element symbol: W), which is a highly heat-resistant metal, into a hairpin-like shape and connecting it to an electrode. The tungsten filament emits an electron beam when heated.Product Development BackgroundBecause the TM Series makes it possible to conduct high-precision observation and analysis, even when installationspace is limited, it has come to be a critical tool during the development and quality control of new materials. Recently, the TM Series has contributed to conserving the environment and maintaining people’s health by being used to develop environmentally friendly materials and their manufacturing processes, as well as analyze harmful substances in the atmosphere. In manufacturing environments, the trend of decreasing feature size and stricter quality control has led to an increase in the number of SEM users. However, not all new users have specialized knowledge and operatingskills. Amidst this trend, we developed the TM4000PlusIII and TM4000III to have this sought-after optimization and simplification of observation tasks for the purposes of enabling the acquisition of high-precision data without any variability, regardless of who is operating the microscope or their level of expertise.Key Features1. Making Tasks More EfficientThe automation support feature with the TM4000PlusIII allows for observation procedures, such as stage movement, magnification changes, and imaging, to be saved as recipes. They can then be executed to run automatically with a single click. This makes operations more efficient and standardizes techniques among users. This is beneficial for those looking to automate routine tasks and for users who are concerned about having to manually configure observation conditions.The TM4000PlusIII also features a setting for high-current mode which enables faster operations due to the increasedobservation signal. For example, in particle analysis a large number of measurement points are required which can bevery time consuming to collect. The high-current function shortens measurement time for each location while reducing the overall time involved in such tasks.2. Plan Ahead with the Filament Monitoring FunctionThe microscopes come equipped with new support features to ensure they can be used with peace of mind at all times. One example is the filament indicator feature, which allows users to track the filament life on screen, preventinginstances of observations being interrupted due to filament replacements occurring mid-observation.3. Ideal for Educational PurposesThe TM Series is equipped with low-vacuum and high-sensitivity backscattered electron detectors, which eliminate the need for complicated pretreatment processes. This makes it possible to conduct observations on a variety of sampleswith ease, enabling the TM Series to be utilized in educational settings.Additionally, as digital skill development becomes a critical subject in educational settings, the TM4000PlusIII allowusers to experience and learn important programming concepts such as “sequential execution,” “repetition,” and “conditional branching” via the automation support features.The TM4000PlusIII and TM4000III will be exhibited at JASIS 2024 at the Makuhari Messe International ExhibitionHalls in Chiba, Japan, from September 4 through September 6, 2024.Hitachi High-Tech aims to ship a target total of 6,000 TM Series units across the global market as quickly as possible to contribute to manufacturing worldwide. Hitachi High-Tech will continue to refine our core analysis technologies, and provide measurement and inspection solutions that support R&D and quality control operations in a wide range of fields, in order to help improve people's QoL (Quality of Life) and to resolve social issues related to the environment, resilience, and security and safety.About Hitachi High-TechHitachi High-Tech, headquartered in Tokyo, Japan, is engaged in activities in a broad range of fields, includingmanufacture and sales of clinical analyzers, biotechnology products, radiation therapy systems, semiconductor manufacturing equipment, analytical instruments, and analysis equipment. Also, we provide high value-added solutions in industrial fields such as mobility, connected, environment and energy, etc. Through business based on our core Observation, Measurement and Analysis technologies, we will contribute to the realization of a sustainable society by solving social issues.The company's consolidated revenues for FY2023 were approx. JPY 670.4 billion. For further information, visit www.hitachi-hightech.com/global/en/Business Contact:Takeshi KamimuraGlobal Sales Planning Dept.Beam Technology & Analytical Systems Business Div., Core Technology & Solutions Business GroupHitachi High-Tech CorporationEmail: takeshi.kamimura.jj@hitachi-hightech.com Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO and CAMBRIDGE, Mass., Aug 22, 2024 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc.announced today that the humanized amyloid-beta(Aβ) monoclonal antibody “Leqembi®” (brand name, generic name: lecanemab) has been granted a Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain.1 Lecanemab is indicated for the treatmentof mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD) in adult patients that are apolipoprotein Eε4 (ApoE ε4)* heterozygotes or non-carriers.1 Lecanemab becomes the first treatment for early AD (MCI and mild dementia due to AD)2 that targets an underlying cause of the disease, to be authorized in a country in Europe.1Lecanemab selectively binds to Aβ aggregate species, with preferential activity for toxic Aβ protofibrils** (as well as fibrils, which are a major component of Aβ plaques).2,3,4 It binds to these aggregate Aβ species to neutralize and clear them from the brain.2,3,4The approval was primarily based on Phase 3 data from Eisai’s global, placebo-controlled, double-blind, parallel-group, randomized Clarity AD clinical trial, in which the medicine met its primary endpoint (change from baseline in the Clinical Dementia Rating Sum of Boxes [CDR-SB]† at 18 months) and all key secondary endpoints with statistically significant results.2 Inthe indicated population in Great Britain, the most common adverse reactions were infusion-related reaction, amyloid-related imaging abnormalities with hemorrhage (small spots of bleeding) (ARIA-H)‡, fall, headache and amyloid-related imaging abnormalities with cerebral edema (build-up of fluid) (ARIA-E)‡‡.1In the United Kingdom, it is estimated that 982,000 people are living with dementia,5 and AD is the cause in 60-70% of people with dementia.6 These numbers are expected to rise, as the population ages.5,6Eisai is working collaboratively with the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the National Health Service (NHS) to make this medicine available to eligible people living with early AD as soon as possible.Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. In Great Britain, Eisai and Biogen will co-promote the medicine, with Eisai distributing the product as the Marketing Authorization holder.*Apolipoprotein E is a protein involved in the metabolism of fats in humans. It is implicated in AD.**Protofibrils are thought to be the most toxic Aβ species that contribute to brain damage in AD and play a major role in the cognitive decline of this progressive and devastating disease. Protofibrils can cause neuronal damage in the brain, which can subsequently adversely affect cognitive function through multiple mechanisms. 7 The mechanism by which this occurs has been reported not only by increasing the formation of insoluble Aβ plaques, but also by directly damaging signaling between neurons and other cells. It is believed that reducing protofibrils may reduce neuronal damage and cognitive impairment, potentially preventing the progression of AD.8†CDR-SB is a commonly used diagnostic tool, which can help to stage dementia due to AD.9 It is a global cognitive and functional scale that measures six domains of functioning, including memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care.9‡ARIA-H: amyloid-related imaging abnormalities with hemorrhage (microhemorrhages, and superficial siderosis).‡‡ARIA-E: amyloid-related imaging abnormalities with oedema (edema/effusion).More information can be found in the Summary of Product Characteristics and Patient Information leaflets which will be published on the MHRA Products website within 7 days of approval.MEDIA CONTACTSEisai Co., Ltd.Public Relations Department TEL: +81 (0)3-3817-5120Eisai Europe, Ltd.EMEA Communications Department+44 (0) 7974-879-419Emea-comms@eisai.netBiogen Inc.Jack Cox+ 1-781-464-3260public.affairs@biogen.comEisai Inc. (U.S.)Libby Holman1-201-753-1945Libby_Holman@eisai.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations Department TEL: +81 (0) 3-3817-5122Biogen Inc.Chuck Triano+ 1-781-464-2442IR@biogen.comAbout lecanemab (Leqembi®)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).2,3Lecanemab’s approval in Great Britain was primarily based on Phase 3 data from Eisai’s global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results.1,2 Clarity AD was a Phase 3global, placebo-controlled, double-blind, parallel-group, randomized study in 1,795 patients with early AD (MCI or milddementia due to AD, with confirmedpresence of amyloid pathology), of which 1,521 were in the indicated population in the label in Great Britain (ApoE ε4heterozygotes or non-carriers).1 Of the total number of patients randomized 31% were non-carriers, 53% were heterozygotes and 16% were homozygotes.1 The treatment group was administered lecanemab 10 mg/kg bi-weekly, with participants allocated in a 1:1 ratio to receive either placebo or lecanemab for 18 months.1The primary endpoint was the global cognitive and functional scale, CDR-SB.1 In the Clarity AD clinical trial, treatment with lecanemab, in the indicated population in Great Britain (ApoE ε4 heterozygotes or non-carriers), reduced clinical decline on CDR-SB by 33% at 18 months compared to placebo.1 The mean CDR-SB score at baseline was approximately 3.2 in both groups.1 The adjusted least-squares mean change from baseline at 18 months was 1.15 with lecanemab and 1.73 with placebo(difference, −0.58; 95% confidence interval [CI], −0.81 to −0.34; P<0.00001).1 CDR-SB is a global cognitive and functional scale that measures six domains of functioning, including memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care.9In addition, the secondary endpoint from the AD Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-MCI-ADL), which measures information provided by people caring for patients with AD, noted 39% less decline compared to placebo at 18 months.1 The adjusted mean change from baseline at 18 months in the ADCS-MCI-ADLscore was −3.5 in the lecanemab group and −5.7 in the placebo group (difference, 2.2; 95% CI, 1.3 to 3.1; P<0.00001).1 The ADCS-MCI-ADL assesses the ability ofpatients to function independently, including being able to dress, feed themselves and participate in community activities.In the indicated population (ApoE ε4 heterozygotes or non-carriers), the most common adverse reactions were infusion-related reaction (26%), ARIA-H (13%), fall (11%), headache (11%) and ARIA-E (9%).1Lecanemab is licensed in the U.S., 10 Japan, 11 China, 12 South Korea, 13 Hong Kong, 14 Israel, 15 the United Arab Emirates16 and Great Britain1 and marketed in the U.S., Japan and China. Eisai has also submitted applications for approval of lecanemab in 10 countries and regions, including the European Union.This medicine is subject to additional monitoring. This will allow quick identification of new safety information.About NHS, NICE and SMCThe NHS is a public healthcare system with the principle of providing free medical services to citizens. The NICE and the SMC are independent bodies that carry out assessments on the status of all newly licensed medicines, all new formulations of existing medicines and new indications for established products regarding their health benefits and price justification as advisory boards to the NHS about whether or not a newly licensed drug should be accepted for use under national health insurance.About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisaiserves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on theantibody back-up was signed in May 2015.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities,manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us onX, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com.Follow Biogen on social media – Facebook, LinkedIn, X, YouTube. The website and social media channels are intended for audiences outside of the UK and Europe.Biogen Safe HarborThis news release contains forward-looking statements, about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof; thetreatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs; including lecanemab; and risks and uncertainties associated with drug development and commercialization. These statements may be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "possible," "potential," "will," "would" and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small numberof research and development programs result in commercialization of a product. Results in early-stage clinical studies may notbe indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements.These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation unexpected concerns that may arise from additional data, analysis or results obtained during clinical studies; the occurrence of adverse safety events; risks of unexpected costs or delays; the risk of other unexpected hurdles; regulatory submissions may take longer or be more difficult to complete than expected; regulatoryauthorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of Biogen's drug candidates; including lecanemab; actual timing and content of submissions to and decisions made by the regulatory authorities regarding lecanemab; uncertainty of success in the development and potential commercialization of the medicine; failure to protect and enforce Biogen's data, intellectual property and other proprietary rights and uncertaintiesrelating to intellectual property claims and challenges; product liability claims; and third party collaboration risks, results ofoperationsand financial condition. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ fromBiogen's expectations in any forward-looking statement. Investors should consider this cautionary statement as well as the riskfactors identified in Biogen's most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securitiesand Exchange Commission. These statements speak only as of the date of this news release. Biogen does not undertake anyobligation to publicly update any forward-looking statements.(1) Lecanemab Great Britain Summary of Product Characteristics(2) van Dyck, H., et al. Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine.2023;388:9-21. https://www.nejm.org/doi/full/10.1056/NEJMoa2212948.(3) Johannesson, M., et al. Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains. Molecular and Cellular Neuroscience. 2024;130:103949. https://doi.org/10.1016/j.mcn.2024.103949.(4) Sehlin, D., et al. Large aggregates are the major soluble Aβ species in AD brain fractionated with density gradient ultracentrifugation. PLoS One. 2012;7(2):e32014. https://doi.org/10.1371/journal.pone.0032014.(5) Alzheimer’s Society. 2024. The economic impact of dementia. Available at: https://www.alzheimers.org.uk/about-us/policy-and-influencing/dementia-scale-impact-numbers. Last accessed: August 2024.(6) World Health Organization. 2023. Dementia. Available at: https://www.who.int/news-room/fact- sheets/detail/dementia. Last accessed: August 2024(7) Amin, L., Harris, D.A. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxicoligomers. Nature Communications. 2021;12:3451. doi:10.1038/s41467-021-23507-z. (8) Ono, K., Tsuji, M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. International Journal of Molecular Sciences. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.(9) Morris, J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-2414.(10) U.S. Food and Drug Administration. 2023. FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval. Last accessed: August 2024.(11) Reuters. 2023. Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen. Last accessed: August 2024.(12) The Pharma Letter. 2024. Brief - Alzheimer drug Leqembi now approved in China. Last accessed: August 2024.(13) Pharmaceutical Technology. 2024. South Korea’s MFDS approves Eisai-Biogen’s LEQEMBI for Alzheimer’s. Last accessed: August 2024.(14) Pharmaceutical Technology. 2024. Hong Kong approves Leqembi for Alzheimer’s treatment. Last accessed: August 2024.(15) BioSpace. 2024. Leqembi approved for the treatment of Alzheimer’s disease in Israel. Last accessed: August 2024.(16) United Arab Emirates Ministry of Health & Prevention. 2024. Registered Medical Product Directory. Leqembi. Last accessed: August 2024. Copyright 2024 JCN Newswire via SeaPRwire.com.

Toyota City, Japan, Aug 22, 2024 - (JCN Newswire via SeaPRwire.com) - TOYOTA GAZOO Racing (TGR) began accepting orders today for the new GR Supra GT4 EVO2, for which vast feedback from racing teams and drivers around the world was leveraged to achieve higher levels of performance, reliability, and operability.Since the launch of the GR Supra GT4 in 2020, thanks to the support of race organizers and customers, cumulative sales(1) of the model have surpassed 120 units. The efforts of racing teams and drivers have enabled it to win GT4-series races and international races in 11 countries and regions, earn more than 500 podium finishes(2), and become the class champion in three regions: Asia, the United States, and Europe.An updated GR Supra GT4 EVO for the 2023 season featured improved braking, handling, and engine performance, making the car easier to drive for drivers of various skill levels. Yet, after that update, with there being no end to its efforts to make ever-better motorsports-bred cars, TGR continued to travel to race tracks around the world to directly receive valuable feedback from racing teams and drivers that can only be obtained under the extreme conditions of racing. Advancing its "driver-first car-making" approach for leveraging such insights into development, TGR has set the race debut of the GR Supra GT4 EVO2, with improved performance, reliability, and operability, at the start of the 2025 season.Specifically, ABS maps were meticulously re-tuned through driving by various drivers on circuits in Japan and Europe to enable optimal braking and cornering based on tire type and wear and the condition of the course. Additionally, downshifting time has been reduced by fine-tuning the rev matching through a software update, leading to enhanced deceleration control during braking for increased cornering speed. Also, in addition to improving the cooling performance of the engine, brakes, and drivetrain, cockpit temperatures have been optimized to make the car easier to drive even in harsh conditions, helping to maintain a high level of performance. These improvements make the GR Supra GT4 EVO2 easier to drive not only for professional racers but also for amateur drivers ambitiously competing in GT4 races worldwide.The GR Supra GT4 EVO2 is scheduled to make its world debut in January 2025 in the first round of the IMSA Michelin Pilot Challenge, held in conjunction with the 24 Hours of Daytona.GT4 sales and customer support (spare parts sales and technical support) will be handled by TOYOTA GAZOO Racing Europe GmbH in Europe, TRD U.S.A., Inc. in North America, Toyota Customizing and Development Co., Ltd. in Japan and other countries in Asia (excluding China), and Toyota Motor (China) Investment Co., Ltd. in China.(1) Including the GR Supra GT4 EVO(2) As of the end of July 2024For more information, visit https://global.toyota/en/newsroom/toyota/41393991.html. Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO, Aug 22, 2024 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI), together with Kirin Group companies Kirin Beverage Co., Ltd. and Kirin Group Logistics Co., Ltd., in August will begin a joint demonstration aimed at establishing elemental technologies for the automation of inbound and outbound processes at beverage warehouses, and the loading and unloading of trucks. The joint demonstration will be conducted at LogiQ X Lab, a demonstration facility located within Yokohama Hardtech Hub (YHH), MHI's co-creation space in Honmoku, Yokohama, and at Kirin Group Logistics sites. The demonstration is scheduled to conclude by March 2026.For this demonstration, as part of the "Smart Connections" solutions incorporating the ΣSynX (Sigma Syncs) technology(Note1) that MHI is currently researching and developing, MHI will utilize a new type of unmanned forklift that is currently under development equipped with ΣSynX, with the aim of establishing elemental technologies that enable flexible autonomous operation and safe human-machine coordination, including appropriate load assortment in warehouse work, altering of operational routes in response to changes in placement locations and storage conditions, and highly efficient storage methods. Through this joint demonstration, MHI aims for future automation of the entire cargo handling process, from the unloading of trucks to handling of inbound and outbound warehouses process, and loading onto trucks.MHI is steadily advancing efforts to utilize "Smart Connections" solutions incorporating the ΣSynX (Sigma Syncs) technology for automation and intelligence of normal logistics warehouse work, which up to now has been conducted safely and efficiently through the expertise, experience and skills of operators, focusing on the three areas of picking, inbound and outbound processes, and the loading and unloading of trucks. Following picking, which is the handling of cargo in warehouses, MHI will pursue development and verification to support the implementation of "Smart Connections" solutions for warehouse operations in the logistics industry. MHI and Kirin Group conducted a joint demonstration of automated picking from November 2022 to June 2023.(Note2) This demonstration verified its effectiveness at logistics sites, and an automated picking solution is scheduled to start operation at Kirin Group's Ebina Logistics Center in Kanagawa Prefecture from December 2024. This new joint demonstration being conducted by the two companies will accelerate the response to the challenges posed to the logistic industry by regulatory changes implemented in 2024.Going forward, through coordination with Kirin Group for this demonstration program, MHI will work to provide solutions for the various issues faced by the beverage industry due to regulatory changes, such as the shortage of logistics operators, the need for improvement in working conditions, and reducing truck driver working hours and wait times.(1) ΣSynX (Sigma Syncs) is MHI's standard platform for synchronizing and coordinating various types of machinery systems. It consolidates a host of digital technologies that enable optimized operation by making machinery systems intelligent. For more information, please refer to the following press release. www.mhi.com/news/23100501.html(2) For more information on the joint demonstration with Kirin Group for an automated picking solution, please refer to the following press release. www.mhi.com/news/22112101.html　Overview of the Joint DemonstrationImplementation period: August 2024, through March 2026Demonstration sites: MHI's LogiQ X Lab demonstration facility at Yokohama Hardtech Hub (YHH), MHI's demonstration facility at Kobe Shipyard, and Kirin Group Logistics facilities such as Nishi-Nagoya and Amagasaki.Content for the demonstration- Determining of operational processes, including manned work, assuming the introduction of warehouse inbound and outbound process solutions- Determining of operational processes, including manned work, assuming the introduction of unmanned forklifts for loading and unloading trucks- Determining of safety concepts, rules, operating conditions, and other standards for collaborative work with manned and unmanned forkliftsTags: Sigma SynX,Smart InfrastructureAbout MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO, Aug 22, 2024 - (JCN Newswire via SeaPRwire.com) - Techstars Tokyo Accelerator powered by JETRO and Mitsui Fudosan is proud to announce the 12 startups selected for the Class of 2024. These promising, early-stage companies are addressing challenges in categories such as Women’s Health, Gaming, Animation, Productivity Enhancement, B2B Business Intelligence, Robotics and more.Taking place in the rapidly growing tech ecosystem of Tokyo, the three-month mentorship-driven program is bringing together founders from across the globe from countries of Finland, India, Indonesia, U.S. and Vietnam along with six Japanese companies. The 2024 class was chosen for innovative products and solutions in areas that will revolutionize how entertainment industries work, how the companies manage their data, and how people live and work better.“We are thrilled to welcome the very first class of Techstars Tokyo Accelerator program,” said Yuki Shirato, Managing Director at Techstars. “This exceptionally talented and diverse group of founders demonstrates tremendous potential and we’re eager to offer our full support leveraging our network of mentors, investors and talents locally and globally and growth-focused tools and workshops, to propel them towards success.”Demo Day is scheduled on November 12th, 2024, where founders will have an opportunity to pitch their businesses to a community of mentors and potential investors.Introducing our inaugural class for the Techstars Tokyo Accelerator!- Aman (Jakarta, Indonesia)Supercharges customized employee health benefits for micro, small and medium enterprises- Amatama (Nagoya, Japan)Optimizes hierarchical computational technology development for humanoids to completely replace labor- Assethub (California, US)Provides an easy way to create unique 3D models from pictures using AI- Digital Will Inc. (Tokyo, Japan)Democratizes gaming with our AI-enhanced platform, WORTAL, for game developers- Dondon Technologies, Inc. (New Jersey, US)Accelerates 2D anime production with AI-assisted drawing tools- InfraHive (Rajasthan, India)Develops data intelligence for finance, analytics and customer teams of enterprises- March Health (California, US)Revolutionizes women’s health (endometriosis) with an AI-first clinic in your pocket- Pioneerwork (Tokyo, Japan)Automates and expedites dropshipping for retail e-commerce- Samaria Inc. (Tokyo, Japan)Unleashes the potential of Japanese manga to the world with AI- Saner.AI (Ho Chi Minh, Vietnam)Revolutionizes knowledge management for knowledge workers, particularly people with ADHD- StoryDrops (Helsinki, Finland)Builds a platform of authenticity through creating and sharing audio messages- Undesk (Tokyo, Japan)Provides a multi-player browser to improve team communication and productivityAbout TechstarsTechstars is the most active pre-seed investor in the world having invested through its accelerators in more than 3,800 companies. Founded in 2006, Techstars believes that entrepreneurs create a better future for everyone and great ideas can come from anywhere. Now we are on a mission to invest in an unprecedented number of startups per year enabling more capital to flow to more entrepreneurs around the world. We do this by operating accelerator programs and venture capital funds, as well as by connecting startups, investors, corporations, and cities to help build thriving startup communities. www.techstars.comMedia Contact for TechstarsAmalia Lytleamalia.lytle@techstars.com Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO, Aug 21, 2024 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Motors Corporation (hereafter, Mitsubishi Motors) announced that Team Mitsubishi Ralliart, for which the company provides technical support, has won fifth place overall in the Asia Cross Country Rally (hereafter, AXCR) 2024, held in Thailand from August 11 to 17, with the Triton1 (T1 specification, or modified cross-country vehicle). The total distance covered was 2,075.54 kilometers (km), including 939.58 km2 of special stages, and Katsuhiko Taguchi finished in fifth place overall with a total time of 15 hours, 34 minutes and 52 seconds.In the overall standings, Kazuto Koide, who competed for the first time, placed 24th, and Sakchai Hantrakul placed 27th. Chayapon Yotha retired from first place overall in Leg 5, ending in 42nd overall.This year’s AXCR held its ceremonial start on August 11 at the landmark clock tower in Surat Thani, Thailand. The rally proper began with Leg 1 the following day, and Leg 2 took the participants from Surat Thani to Hua Hin, covering over 550 km and making it the longest section of the entire competition. Leg 3 was a special stage in the Hua Hin area, and with Leg 4, the rally headed to Kanchanaburi, on an undulating track through mountainous terrain. Leg 4 was the toughest special stage of the six days, as many teams struggled with the route over the mountains with rocky terrain, and more than 10 teams were penalized for failing to finish within the allowed time. Leg 5 was the longest special stage in this year's competition, covering 228.87 km in the Kanchanaburi area, and the competition concluded with Leg 6 on August 17, finishing at Skywalk Avenue, close to the new tourist attraction Skywalk Kanchanaburi.This was the second year for Katsuhiko Taguchi, who started from seventh position. Although he had a hard time with the challenging course settings, he drove carefully and steadily to complete each day's special stage and improved his position from eighth place overall last year to finish in fifth place overall.Sakchai Hantrakul started from 30th position and jumped up to fifth place in Leg 1, but was troubled by course errors and vehicle issues, finishing in 27th place.Kazuto Koide, who competed as an employee driver, struggled at first with the course, but he continued to drive steadily, demonstrating his adaptability and supporting his teammates who got stuck or had vehicle trouble. In the end, he finished in 24th place overall.The previous year's 3rd place overall winner, Chayapon Yotha started furthest forward for Team Mitsubishi Ralliart and drove steadily, setting times that placed him in the top ranks day after day. By the end of Leg 4, which was the toughest of all the special stages, the Triton's high off-road handling performance showed its true potential, putting him in the overall lead with a margin of over 20 minutes ahead of second place. However, due to vehicle trouble in Leg 5, he was unable to continue and had to retire from the rally.Comment from Hiroshi Masuoka, team director of Team Mitsubishi Ralliart“This year's Triton was perfected with enhanced performance, showing powerful driving that covered the displacement gap with our rivals and even took the overall lead at one point. It is unfortunate that we were unable to win, but the Triton was able to fully demonstrate its excellent off-road capabilities that Mitsubishi vehicles have honed over the decades. After returning to Japan, Koide, an employee driver who had competed for the first time, and others will reflect the valuable data and knowledge gained from this rally in the development of production vehicles, adding a new chapter to our tradition of leveraging motorsports experience for vehicle development. We will undergo rigorous tests again, and Team Mitsubishi Ralliart will make a comeback next year. We would like to thank our sponsors for their generous support and our fans around the world for their enthusiastic cheering."Comment from Katsuhiko Taguchi, driving Car #107 for Team Mitsubishi Ralliart“The 2024 Triton rally car was packaged at a high level and was just easy to drive. I am happy to have improved my position from last year, but I am also disappointed because I had a good feeling that I could aim for a higher position. We will use this years’ experience as feedback to further improve the driving performance of the Triton next year, so that we can stay competitive at the top.”Comment from Kazuto Koide, driving Car #137 for Team Mitsubishi Ralliart“The Triton rally car I drove was a 2023 model based on a production car and has a drive mode called 4LLc for rocky terrain. Using this mode, I was able to climb a nearly 40-degree incline without difficulty while towing my teammate's car, and I was reminded once again of the high off-road performance of the Triton production car. I would like to feedback what I have learned as a driver through this rally to develop future Mitsubishi vehicles that are strong and dependable on rough roads.”1st:Mana Pornsiricherd (Toyota Hilux Revo)14 hours 22 minutes 00 seconds2nd:Suwat Limjirapinya (Isuzu D-Max)14 hours 25 minutes 47 seconds3rd:Thongchai Klinkate (Isuzu D-Max)14 hours 36 minutes 24 seconds4th:Ikuo Hanawa (Toyota Fortuner)14 hours 56 minutes 48 seconds5th:Katsuhiko Taguchi (Mitsubishi Triton)15 hours 34 minutes 52 seconds6th:Olan Sornsirirat (Isuzu D-Max)15 hours 35 minutes 34 seconds・24th:Kazuto Koide (Mitsubishi Triton)23 hours 08 minutes 37 seconds27th:Sakchai Hantrakul (Mitsubishi Triton)24 hours 51 minutes 52 seconds42nd:Chayapon Yotha (Mitsubishi Triton)DNF (Did Not Finish)Comment from Kei Takeoka, an automotive journalist who accompanied Team Mitsubishi Ralliart with the Delica Mini support car“This year's AXCR had rock sections and river crossings, making it far more challenging than I had imagined. Moreover, the course itself was difficult – the vigorous plants of Thailand grew wildly from the time the roadbook was created until the actual rally, so we had to drive through areas that did not look very much like roads. That must have made navigation difficult for the co-driver. I drove the Delica Mini support car, and everywhere we went, the Delica Mini and Delimaru, its official character, were very popular. Whenever we stopped in town, a photo session would start, and many people took videos while we were driving. The Delica Mini may become a very popular model in the Bangkok area. Of course, the Delica Mini was very capable on rough roads, and it was even reliable on Thailand's red dirt off-roads, as well as cracked, pothole-filled paved roads.”Daily reportsDaily reports from August 11, the first day of the competition, to the last leg on August 17 are available on Mitsubishi Motors' special AXCR website. www.mitsubishi-motors.com/en/brand/ralliart/axcr/axcr2024/1. Sold as L200 in some markets2. The actual distance was shortened due to course changes.About Mitsubishi MotorsMitsubishi Motors Corporation (TSE:7211) — a member of the Alliance with Renault and Nissan — is a global automobile company based in Tokyo, Japan, which has about 28,000 employees and a global footprint with production facilities in Japan and the ASEAN region. Mitsubishi Motors has a competitive edge in SUVs, pickup trucks and plug-in hybrid electric vehicles, and appeals to ambitious drivers willing to challenge convention and embrace innovation. Since the production of our first vehicle more than a century ago, Mitsubishi Motors has been a leader in electrification — launched the i-MiEV, the world’s first mass-produced electric vehicle in 2009, followed by the Outlander PHEV, the world’s first plug-in hybrid electric SUV in 2013. With a target of increasing the sales ratio of electrified vehicles to 100% by 2035, Mitsubishi Motors will deliver models that embody Mitsubishi Motors-ness and contribute to the realization of a carbon-neutral society. For more information on Mitsubishi Motors, please visit the company's website at www.mitsubishi-motors.com/en/ Copyright 2024 JCN Newswire via SeaPRwire.com.

KYOTO, JAPAN, Aug 14, 2024 - (JCN Newswire via SeaPRwire.com) - Valuufy, a pioneering fintech startup drawn from a decades’ work in measuring and creating sustainable value at Doshisha University’s Value Research Center, has launched with its groundbreaking ValuuCompass, a comprehensive framework set to transform sustainable business practices and sustainability investing by providing a fully transparent and actionable framework for assessing and improving sustainability performance.The current state of sustainability reporting:·  Confusing and inefficient for companies·  Multiple different standards and metric·  Emphasis on past activities rather than future strategies·  Difficult to capture real impacts on people and the environment·  No reliable benchmark for investors to assess sustainability risks and opportunitiesValuuCompass addresses precisely these challenges.The ValuuCompass addresses a critical gap in the market: the lack of a holistic, transparent system for assessing a company's true stakeholder impacts and sustainability risks that arise from these. At the heart of this new product is the Value Model, which has synthesized more than 1,200 individual impact measurements from leading global ESG and sustainability frameworks into a clear goal-based model to measure stakeholder impacts and value creation. With this new assessment system, Valuufy offers businesses and investors a clear, actionable view of value creation that goes far beyond traditional sustainability and ESG metrics. "In an era where 'value washing' - the pretence of sustainable value creation - poses significant financial and reputational risks, both companies and investors need a reliable compass," said Kyle Barnes, CEO of Valuufy. "Valuufy's products and services provide these capabilities, offering a level of transparency and insight that goes beyond all other existing solutions."Dr. Philip Sugai, Director of Research at Valuufy and Director at the Value Research Center, emphasized the revolutionary approach that Valuufy is taking: "The current systems underlying sustainability and ESG are fundamentally broken, focusing on backwards-looking disclosures rather than forward-looking strategies.  Valuufy was established to change this paradigm, helping businesses to shift their focus to creating real, and measurable value across their key stakeholders."Valuufy’s ongoing activities aim to bring this important mindset to business strategy creation for businesses of all sizes. "Today, we're not just launching a new tool; we're setting a new standard for sustainable business and investing," added Marco Koeder, Chief Marketing Officer. By 2030, we aim to establish the Value Model as the global benchmark for measuring and creating sustainable value."Benefits of ValuuCompass for Companies:·  First universal, objective standard to measure real impact on people and the planet·  Provides actionable recommendations for improvement·  Enhances performance in the sustainability reporting framework·  Transforms complex data into clear, strategic insightsBenefits of ValuuCompass for Investors:·  Enables truly informed decisions on sustainability risks and opportunities·  Offers rigorous, quantifiable metrics for portfolio assessment·  Aligns perfectly with the financial sector's data-driven approach·  Provides a competitive edge in sustainable investingDiscover how Valuufy is revolutionizing the future of sustainability at www.valuufy.com.About ValuufyValuufy Inc seeks to transform how the world understands and acts on sustainability. Founded in 2024, Valuufy is a registered Japanese startup in Kyoto, Japan, born of 10 years of academic value research at Doshisha University and the Value Research Center. Led by an international team with expertise in value research, sustainability strategies, innovative technologies, business development, and ESG assessments, Valuufy provides a suite of products and services to promote value-creation activities across stakeholders for businesses of all sizes - to set new standards in transparent, data-driven decision-making in the realm of sustainability and value creation. For more, visit www.valuufy.com.The Value Research Center was officially established at Doshisha University in Kyoto, Japan, in November 2021 to develop a system for measuring, monitoring, assessing, and reporting on organizations' value creation and destruction impacts on various stakeholder groups. The result is the Value Model, which forms the foundation for ValuuCompass.Contact:Press/MediaE: news@valuufy.comT: +81-90-9742-0860Marco KoederE: marco@valuufy.com T: +49-175-999-8647 Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO and CAMBRIDGE, Mass., Aug 14, 2024 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (lecanemab) for the treatment of Alzheimer’s disease (AD). Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD), the population in which treatment was initiated in clinical trials.LEQEMBI selectively binds to soluble Aβ aggregates (protofibrils*), as well as insoluble Aβ aggregates (fibrils) which are a major component of Aβ plaques, thereby reducing both Aβ protofibrils and Aβ plaques in the brain. LEQEMBI is the first approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism. LEQEMBI is also approved in the U.S., Japan, China, South Korea, Hong Kong, and Israel, and is being marketed in the U.S., Japan, and China.LEQEMBI’s approval is based on the large global Phase 3 Clarity AD study. In the Clarity AD study, LEQEMBI met its primary endpoint and all key secondary endpoints with statistically significant results.(1),(2) In the UAE, it is reported that 4.09% of those over 60 years old have dementia.(3) AD is considered the most common cause of dementia, typically accounting for 60-70% of cases.(4)Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. Biogen will commercialize LEQEMBI in the UAE.* Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.(5) Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.(6) About lecanemab (LEQEMBI®)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).LEQEMBI’s FDA approval was based on Phase 3 data from Eisai’s, global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results.1,2 The primary endpoint was the global cognitive and functional scale, Clinical Dementia Rating Sum of Boxes (CDR-SB). In the Clarity AD clinical trial, treatment with LEQEMBI reduced clinical decline on CDR-SB by 27% at 18 months compared to placebo. The mean CDR-SB score at baseline was approximately 3.2 in both groups. The adjusted least-squares mean change from baseline at 18 months was 1.21 with LEQEMBI and 1.66 with placebo (difference, −0.45; 95% confidence interval [CI], −0.67 to −0.23; P<0.001). In addition, the secondary endpoint from the AD Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-MCI-ADL), which measures information provided by people caring for patients with AD, noted a statistically significant benefit of 37% compared to placebo. The adjusted mean change from baseline at 18 months in the ADCS-MCI-ADL score was −3.5 in the LEQEMBI group and −5.5 in the placebo group (difference, 2.0; 95% CI, 1.2 to 2.8; P<0.001). The ADCS MCI-ADL assesses the ability of patients to function independently, including being able to dress, feed themselves and participate in community activities. The most common adverse events (>10%) in the LEQEMBI group were infusion reactions, ARIA-H (combined cerebral microhemorrhages, cerebral macrohemorrhages, and superficial siderosis), ARIA-E (edema/effusion), headache, and fall.LEQEMBI is approved in the U.S., Japan, China, South Korea, Hong Kong and Israel for the treatment of MCI due to AD and mild AD dementia. Eisai has also submitted applications for approval of LEQEMBI in 11 countries and regions. A supplemental Biologics License Application (sBLA) for intravenous maintenance dosing was submitted to the U.S. Food and Drug Administration (FDA) in March 2024, which was accepted in June 2024. The rolling submission of a Biologics License Application (BLA) for maintenance dosing of a subcutaneous injection formulation, which is being developed to enhance convenience for patients, was initiated in the U.S. under Fast Track status in May 2024.Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai. Co., Ltd.), us.eisai.com (for U.S. headquarters: Eisai, Inc.) or www.eisai.eu (for Europe, Middle East, Africa, Russia, Australia and New Zealand headquarters: Eisai Europe Ltd.), and connect with us on X (global and U.S), LinkedIn (for global, U.S. and EMEA) and Facebook (global).About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTubeReferences(1) Eisai presents full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer's disease at Clinical Trials on Alzheimer's Disease (CTAD) conference. Available at: https://www.eisai.co.jp/news/2022/news202285.html.(2) van Dyck, H., et al. Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine. 2023;388:9-21. https://www.nejm.org/doi/full/10.1056/NEJMoa2212948.(3) Qassem T., et al, Prevalence and economic burden of dementia in the Arab world. BJPsych Open. 2023 Jul; 9(4): e126. https://doi.org/10.1192%2Fbjo.2023.517. (4) World Health Organization. Dementia Fact Sheet. March 2023. Available at: https://www.who.int/news-room/fact-sheets/detail/dementia.(5) Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z(6) Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.Biogen Safe HarborThis news release contains forward-looking statements, about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including  lecanemab; and risks and uncertainties associated with drug development and commercialization. These statements may be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "possible," "potential," "will," "would" and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements.These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation unexpected concerns that may arise from additional data, analysis or results obtained during clinical studies; the occurrence of adverse safety events; risks of unexpected costs or delays; the risk of other unexpected hurdles; regulatory submissions may take longer or be more difficult to complete than expected; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of Biogen's drug candidates, including lecanemab; actual timing and content of submissions to and decisions made by the regulatory authorities regarding lecanemab; uncertainty of success in the development and potential commercialization of lecanemab; failure to protect and enforce Biogen's data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; and third party collaboration risks, results of operations and financial condition. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Biogen's expectations in any forward-looking statement. Investors should consider this cautionary statement as well as the risk factors identified in Biogen's most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements.MEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Biogen Inc.Jack Cox+ 1-781-464-3260public.affairs@biogen.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Biogen Inc.Chuck Triano+ 1-781-464-2442IR@biogen.com Copyright 2024 JCN Newswire via SeaPRwire.com.